Systemic Inflammatory Indices as Predictors of Adverse Outcomes in Pregnancy With Vascular Events
Pregnancy is already a state of controlled inflammation, vascular adaptation, and haemostatic change. When vascular events occur, that balance can shift quickly, sometimes before clinical deterioration becomes obvious. A retrospective cohort study examining inflammatory indices in pregnancies complicated by vascular events adds to a growing body of evidence that routine blood count data may help identify patients at higher risk of adverse outcomes.
The study’s central message is clinically relevant: composite inflammatory markers derived from complete blood count parameters appear to carry prognostic value in this high-risk obstetric group. These indices are not replacements for blood pressure trends, Doppler findings, biochemical markers, or clinical judgement. They may, though, offer a low-cost adjunct for risk assessment, especially in settings where advanced biomarkers are not readily available.
This article is for informational and educational use only. It does not replace local protocols, specialist consultation, or individualised clinical decision-making.
Why systemic inflammation matters in pregnancy with vascular events
Normal pregnancy requires major vascular and immune changes. The maternal circulation expands, endothelial function adapts, and immune tolerance develops at the maternal-foetal interface. A measured inflammatory response supports implantation, placentation, and labour.
Vascular pregnancy complications often involve a more dysregulated pattern. Endothelial activation, platelet consumption or activation, neutrophil response, lymphocyte changes, and altered monocyte activity may all contribute to placental dysfunction and maternal morbidity.
The term “vascular events” can include conditions such as:
Hypertensive disorders of pregnancy, including pre-eclampsia
Placental insufficiency and foetal growth restriction
Placental abruption
Thrombotic events
Other placental-mediated complications with maternal or foetal vascular involvement
These disorders differ in presentation, but many share overlapping inflammatory and vascular pathways. That is why indices built from neutrophils, lymphocytes, platelets, and monocytes have attracted interest.
The value of SYSTEMIC INFLAMMATORY INDICES lies in their ability to summarise multiple immune and haemostatic signals into simple ratios or composite scores. In many hospitals, the data required are already available from a complete blood count. That makes them practical, inexpensive, and easy to repeat.
What the retrospective cohort study found
The retrospective cohort study evaluated whether systemic inflammatory markers could predict adverse maternal and perinatal outcomes in pregnancies complicated by vascular events. While the exact thresholds and performance measures depend on the study population and analytical method, the broad findings are clear: higher inflammatory indices were associated with a greater likelihood of adverse outcomes.
The indices assessed in such studies commonly include:
Index | Usual components | Clinical signal reflected |
Neutrophil-to-lymphocyte ratio | Neutrophils and lymphocytes | Innate immune activation relative to adaptive immune balance |
Platelet-to-lymphocyte ratio | Platelets and lymphocytes | Platelet activity and inflammatory state |
Monocyte-to-lymphocyte ratio | Monocytes and lymphocytes | Monocyte-driven inflammation and immune imbalance |
Systemic immune-inflammation index | Platelets, neutrophils, and lymphocytes | Combined platelet and neutrophil activation with lymphocyte suppression |
Systemic inflammation response index | Neutrophils, monocytes, and lymphocytes | Integrated innate immune response |
The key interpretation is not that one index can diagnose a complication by itself. Rather, increased inflammatory indices may identify a subgroup of patients whose vascular event is accompanied by a stronger systemic inflammatory response. That subgroup may be more likely to experience complications such as disease progression, worsening maternal status, emergency delivery, neonatal compromise, or admission-level neonatal care.
Several implications follow from this:
Composite indices may outperform isolated blood count values. A single neutrophil or platelet count may be difficult to interpret in pregnancy. Ratios and composite markers can better reflect immune balance.
Inflammation appears linked to severity. Higher indices may correlate with more severe vascular dysfunction rather than merely the presence of disease.
Timing matters. Indices measured near clinical deterioration may carry different meaning from those measured at diagnosis or in early pregnancy.
Indices work best as adjuncts. Their value is greatest when combined with clinical features, obstetric history, blood pressure, urine protein, liver and renal parameters, coagulation profile, and foetal assessment.
The retrospective design also matters. Such studies can show association, but they cannot prove that high indices cause poor outcomes. They are useful for hypothesis generation and for identifying markers that deserve prospective validation.
How these indices may help predict adverse outcomes
Pregnancy with a vascular event often requires repeated decisions under uncertainty. Should the patient be managed as an outpatient or admitted? How frequently should labs and foetal surveillance be repeated? Is expectant management safe? When should delivery be planned?
Inflammatory indices may help refine these decisions in four practical ways.
They provide a rapid risk signal from routine testing
Complete blood count testing is widely available, including in district-level and resource-constrained settings across India. If inflammatory indices can be calculated from existing results, they add information without requiring a new sample, specialised assay, or high cost.
A patient with a vascular complication and a markedly raised composite inflammatory index may warrant closer observation, particularly if other clinical markers are borderline. This does not mean automatic intervention. It means the threshold for reassessment may be lower.
They can complement maternal clinical assessment
Symptoms such as headache, epigastric pain, reduced foetal movements, or dyspnoea carry major clinical weight. Blood pressure, oxygen saturation, urine testing, and biochemical markers remain central.
Inflammatory indices may add another layer by reflecting systemic activation before overt organ dysfunction appears. For example, in a patient with pre-eclampsia without severe features, a rising inflammatory index over serial tests could support more frequent monitoring, especially if platelet count is falling or liver enzymes are trending upward.
They may support foetal risk stratification
Placental vascular disease can affect foetal growth, amniotic fluid volume, and Doppler flow. Inflammatory indices cannot replace ultrasound or cardiotocography where indicated. They may help identify which patients require more frequent foetal surveillance.
This is especially relevant in pregnancies where maternal findings appear stable but placental function remains uncertain. A high index may direct attention toward closer growth monitoring, umbilical artery Doppler assessment, and timely referral if advanced foetal surveillance is unavailable locally.
They are useful for trends, not just single values
A single inflammatory ratio can be affected by infection, steroid administration, dehydration, stress, labour, autoimmune disease, and other conditions. Serial trends may be more informative.
For clinical use, the direction of change may matter as much as the absolute value. A rising neutrophil-driven index in the context of worsening hypertension or evolving thrombocytopenia should prompt careful review. By contrast, a stable or falling index may support ongoing observation if all other parameters are reassuring.
Why composite inflammatory markers are biologically plausible
The association between inflammatory indices and adverse pregnancy outcomes makes biological sense.
Neutrophils increase during normal pregnancy, but excessive activation can contribute to endothelial injury and oxidative stress. Lymphocyte changes may reflect altered immune regulation. Platelets play a central role in thrombosis, placental perfusion, and microvascular dysfunction. Monocytes can amplify inflammation through cytokine release and endothelial interaction.
In placental-mediated vascular disease, these pathways overlap. A composite index that includes neutrophils, lymphocytes, and platelets may reflect both inflammation and haemostatic activation. That is clinically attractive because adverse outcomes often arise from the combined effect of vascular dysfunction, inflammation, and coagulation changes.
Still, interpretation must remain cautious. Pregnancy itself changes normal haematological ranges. The third trimester differs from the first. Labour, infection, corticosteroids, magnesium sulphate use, and coexisting medical illness can alter blood counts. Local reference ranges and population-specific validation are needed before fixed cut-offs are adopted.
What the findings mean for clinical practice
The study supports a pragmatic approach rather than a dramatic change in care. Systemic inflammatory indices may be considered as part of structured risk assessment in pregnancies with vascular events, especially when clinical severity is uncertain.
Potential recommendations for healthcare providers include the following.
Integrate indices into existing assessment, not as standalone tests
Inflammatory indices should sit beside established parameters:
Blood pressure pattern and antihypertensive requirement
Symptoms suggestive of severe disease
Platelet count, liver enzymes, renal function, and urine protein
Coagulation parameters where indicated
Ultrasound growth assessment and Doppler studies
Gestational age and previous obstetric history
Availability of maternal and neonatal intensive care
A raised index alone should not trigger delivery. A raised index with worsening symptoms, declining platelets, abnormal liver or renal tests, or non-reassuring foetal findings should increase clinical concern.
Standardise when the indices are measured
For meaningful use, teams should define when indices are calculated. Examples include:
At diagnosis of a vascular pregnancy complication
At hospital admission
During routine reassessment in expectant management
Before planned delivery in high-risk patients
When clinical status changes
Without standard timing, comparison across patients becomes difficult. Serial monitoring is most useful when tests are done in a consistent clinical context.
Account for confounders before escalation
Inflammatory indices rise in many conditions unrelated to placental vascular disease. Before acting on a high value, assess for:
Acute infection
Recent corticosteroid exposure
Labour or recent procedure
Autoimmune or inflammatory disease
Haematological disorders
Dehydration or physiological stress
A high index should trigger review, not reflex intervention.
Use local data to define meaningful thresholds
Cut-offs from one retrospective cohort may not apply to every population. Differences in ethnicity, nutrition, baseline anaemia, infection burden, laboratory methods, and referral patterns can affect results.
Hospitals and research groups should validate thresholds within their own settings before embedding them in protocols. This is especially relevant in India, where care settings range from primary centres to tertiary referral units with high-risk obstetric and neonatal services.
Build indices into multidisciplinary pathways
Pregnancies with vascular complications often require input from obstetricians, maternal-foetal medicine specialists, physicians, anaesthetists, haematologists, neonatologists, and critical care teams. Inflammatory indices can support shared risk communication if everyone understands their role and limits.
A practical approach would be to include these markers in a structured high-risk pregnancy review sheet, alongside clinical and biochemical parameters. The goal is not to add complexity, but to make risk assessment more complete.
Limits of the evidence
Retrospective cohort studies are valuable, but they come with clear limits. Data quality depends on existing records. Testing may not be uniform. Sicker patients often undergo more frequent investigations, which can introduce bias. Confounders may not be fully captured.
There is also a broader issue of outcome definition. “Adverse outcome” can include a wide range of events, from maternal ICU admission to preterm birth, emergency caesarean birth, foetal distress, neonatal intensive care admission, or perinatal loss. A marker that predicts one outcome may not predict all with equal strength.
Before these indices can guide major clinical decisions, future studies should address:
Prospective validation in diverse populations
Gestational age-specific reference ranges
Clear timing of blood sampling
Standard definitions of vascular events and adverse outcomes
Comparison with established risk models
Added predictive value beyond routine clinical and laboratory variables
The most useful research will show whether adding inflammatory indices changes management and improves outcomes, not just whether they correlate with risk.
A practical takeaway for high-risk obstetric care
The retrospective cohort study reinforces a clinically sensible idea: vascular pregnancy complications are not purely haemodynamic disorders. They often involve systemic inflammation, endothelial dysfunction, and altered blood cell activity. Indices derived from routine blood counts may help identify patients at higher risk of adverse maternal or perinatal outcomes.
For now, healthcare providers can treat these markers as risk modifiers. They can strengthen concern when the clinical picture is borderline, support closer surveillance, and help prioritise referral or admission in selected patients. They should not replace established assessment, and they should not be used without attention to gestational age, infection, medication exposure, and local context.
The best next step is careful integration. Calculate these indices where data are available, interpret them alongside standard obstetric assessment, and support prospective research that defines reliable thresholds. In pregnancies with vascular events, small signals from routine blood tests may offer meaningful help when the margin for error is narrow.
Comments